FDA clears new use for GE's AdreView SPECT tracer
Article Thumbnail ImageMarch 22, 2013 -- The U.S. Food and Drug Administration has approved a new cardiac indication for the AdreView (iobenguane I-123 injection) SPECT radiopharmaceutical from GE Healthcare.

To get access to this article and all of the content on AuntMinnie.com, create a free account or sign-in now.

Member Sign In:
  MemberID or E-mail Address:

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The FDA cleared AdreView for the scintigraphic assessment of myocardial sympathetic innervation in the evaluation of patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction of 35% or less, according to GE.

    A limited number of tools are available to help assess cardiac disease progression in heart failure patients, and the new agent can help clinicians understand the potential for progression of heart failure, GE said.

    || About || Advertising || AuntMinnieCME.com || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 AuntMinnie.com. All Rights Reserved.